生物标志物在心力衰竭预防、评估与管理中的作用:AHA科学声明
BACKGROUND AND PURPOSE: Natriuretic peptides have led the way as a diagnostic and prognostic tool for the diagnosis and management of heart failure (HF).…
要点
- 利钠肽是心衰诊断和预后工具的先导标志物。
- 新一代标志物与利钠肽联合可能为医疗管理提供附加价值。
- 循环标志物浓度测量可无创提供疾病严重程度信息并辅助诊疗。
核心结论
- 心衰是涉及多种通路和病理过程的复杂综合征,可在循环中以生物标志物形式表现。
- 多种此类标志物已临床可用,监测其血液浓度不仅可提供诊断和严重程度信息,还可改善预后判断和治疗策略。
研究设计与样本
- 写作组通过系统文献综述、已发表的转化和临床研究、临床实践指南及专家意见/声明总结现有证据。
- 文档按美国心脏协会组织分类,提供具体建议、考虑或当代临床实践推荐。
主要发现
- 与心衰相关的多种生物标志物已被充分认识,测量其循环浓度是便捷无创的方法。
- 这些标志物包括利钠肽、可溶性肿瘤抑制素2(sST2)、高敏肌钙蛋白、半乳糖凝集素-3、中段前肾上腺髓质素、胱抑素-C、白介素-6、降钙素原等。
- 需要进一步评估现有和新标志物以指导治疗,并以标准化格式总结数据以改善研究者与从业者间的交流。
临床怎么用
- 监测血液生物标志物浓度可提供心衰诊断和严重程度信息。
- 生物标志物监测可改善预后判断和治疗策略。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Natriuretic peptides have led the way as a diagnostic and prognostic tool for the diagnosis and management of heart failure (HF). More recent evidence suggests that natriuretic peptides along with the next generation of biomarkers may provide added value to medical management, which could potentially lower risk of mortality and readmissions. The purpose of this scientific statement is to summarize the existing literature and to provide guidance for the utility of currently available biomarkers. METHODS: The writing group used systematic literature reviews, published translational and clinical studies, clinical practice guidelines, and expert opinion/statements to summarize existing evidence and to identify areas of inadequacy requiring future research. The panel reviewed the most relevant adult medical literature excluding routine laboratory tests using MEDLINE, EMBASE, and Web of Science through December 2016. The document is organized and classified according to the American Heart Association to provide specific suggestions, considerations, or contemporary clinical practice recommendations. RESULTS: A number of biomarkers associated with HF are well recognized, and measuring their concentrations in circulation can be a convenient and noninvasive approach to provide important information about disease severity and helps in the detection, diagnosis, prognosis, and management of HF. These include natriuretic peptides, soluble suppressor of tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others. There is a need to further evaluate existing and novel markers for guiding therapy and to summarize their data in a standardized format to improve communication among researchers and practitioners. CONCLUSIONS: HF is a complex syndrome involving diverse pathways and pathological processes that can manifest in circulation as biomarkers. A number of such biomarkers are now clinically available, and monitoring their concentrations in blood not only can provide the clinician information about the diagnosis and severity of HF but also can improve prognostication and treatment strategies.
引用
- Chow SL, Maisel AS, Anand I, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017. PMID: 28446515. doi:10.1161/CIR.0000000000000490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。